Equities research analysts at Piper Jaffray started coverage on shares of Oncolytics Biotech (NASDAQ: ONCY) in a research note issued to investors on Monday. The firm set an “overweight” rating and a $6.00 price target on the stock.
Separately, analysts at Bloom Burton downgraded shares of Oncolytics Biotech from a “buy” rating to a “hold” rating in a research note to investors on Tuesday, December 18th.
Six investment analysts have rated the stock with a buy rating, and two have assigned a hold rating to the stock. Oncolytics Biotech presently has a consensus rating of “overweight” and a consensus target price of $7.79.
Shares of Oncolytics Biotech opened at 3.355 on Monday. Oncolytics Biotech has a one year low of $1.60 and a one year high of $5.08. The stock’s 50-day moving average is currently $3.82. The company’s market cap is $257.3 million.
Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company have focused the research and development efforts on the development of REOLYSIN, the cancer therapeutic.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.